TGFBR2 and neoplasm: After treatments, the size, weight, and growth of tumors from LS411N-TβRII DSTYK/KO cells had regressed significantly more than those tumors from LS411N-TβRII control cells (Figures 6A–C), which suggests that DSTYK inhibits chemotherapeutic drug-induced tumor cell death.